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In the present paper, we have investigated early pathophysiological events in graft-versus-host disease (GVHD), a major complica-
tion to hematopoietic stem cell transplantation (HSCT). BLLB/c female mice conditioned with busulfan/cyclophosphamide (Bu-
Cy) were transplanted with allogeneic male C57BL/6. Control group consisted of syngeneic transplanted Balb/c mice. In allogeneic
settings, signiﬁcant expansion and maturation of donor dendritic cells (DCs) were observed at day +3, while donor T-cells CD8+
were increased at day +5 (230%) compared to syngeneic HSCT. Highest levels of inﬂammatory cytokines IL-2, IFN-gamma, and
TNF-alfa at day +5 matched T-cell activation. Concomitantly na¨ ıve T-cells gain eﬀecr-memory phenotype and migrated from
spleen to peripheral lymphoid organs. Thus, in the very early phase of GHVD following Bu-Cy conditioning donor, DCs play an
important role in the activation of donor T cells. Subsequently, donor na¨ ıve T-cells gain eﬀector-memory phenotype and initiate
GVHD.
1.Introduction
Allogeneic hematopoietic stem cell transplantation (HSCT)
is a curative therapy for the treatment of malignant and
nonmalignant disorders. While graft versus leukemia (GVL)
is promoted by donor T-cells [1] and desired when HSCT is
used as a treatment for malignant disorders, the alloreactive
donor T-cells that induce GVL eﬀect may also initiate graft-
versus-host disease (GVHD) [2–4]. GVHD is a serious
complication that limits the use of allogeneic HSCT.
It has been reported that GVHD develops in three
consecutivestages.(1)Inﬂammationcoupledwithacytokine
storm as result of pretransplant conditioning. (2) Activation
of donor T-cells via recipient/donor antigen presenting cells
(APCs).(3)Finally,damageofcertaintissuesbytheactivated
donor T-cells [4–7]. Intestine, skin, liver, and lungs are
the most frequently aﬀected organs, which are assaulted by
alloreactive donor T-cells [8].
Several investigations have shown that the occurrence
and severity of GVHD depend on several factors, including2 Clinical and Developmental Immunology
the intensity of conditioning, the presence and number
of donor T-cells in the graft, and the antigenic disparity
between donor and recipient [9–12]. However, GVHD
may occur in any type of allogeneic setting regardless of
conditioning protocol [13, 14]. In both clinical settings [15]
andinexperimentalmodels[3,16],GVHDmightoccurlong
after DLI-induced GVHD or even without conditioning.
These observations indicate the primacy and importance of
immune competent cells in the pathophysiology of GVHD
[3].
Understanding the cellular and molecular mechanisms
underlying the initiation and development of acute GVHD
is an important issue which can improve our knowledge
and subsequently may help in providing strategies for the
prevention and/or treatment of GVHD. Several studies have
shown that certain recipient and/or donor cell populations
[3, 17–19] and cytokines, for example, IFNγ,T N F α [20]
are involved in the process of GVHD [4, 21]. However,
to our knowledge, only few (if any) studies address the
dynamics of donor and host immune cells expansion and
activation pattern in combination with cytokine proﬁle at
the initiation stage of GVHD in a complete experimental
setup. For instance, by utilizing an in vivo tracking system
Beilhack et al. and Panoskaltsis-Mortari et al. have shown
the migration pattern of donor cells in GVHD, but due to
technical limitation they did not draw a dynamic model to
include the interaction of diﬀerent cell populations from
donor and recipient source [6, 7].
Recently, we introduced a novel mouse model of GVHD
based on chemotherapy conditioning [22]. In the present
paper,weusedthismodeltofollowthedynamicofactivation
and proliferation pattern of donor immune cells in the
secondary lymphoid organs of recipient during the early
phase of GVHD. In parallel, the production of diﬀerent
proinﬂammatory cytokines was also evaluated.
2.MaterialsandMethods
2.1. Animals. Female BALB/c (H-2d) and male C57BL/6
(H-2b) mice, 10–12 weeks old were purchased from Scan-
bur (Sollentuna, Sweden). Mice were maintained under
pathogen-free conditions with controlled humidity (55 ±
5%), 12 hours light/dark, temperature (21◦C ± 2◦C), and
HEPA-ﬁltered air. Animals were kept in individually venti-
lated cages and were fed autoclaved mouse chow and tap
water ad libitum.
2.2. Bone Marrow Transplantation. Recipient mice under-
went transplantation according to the protocol described
previously [22]. Brieﬂy, recipient female BALB/c mice
received busulfan (80mg/kg) for 4 days followed by
cyclophosphamide (200mg/kg) for 2 days. Day −1a n d0
considered as resting and BMT days, respectively.
Male C57BL/6 and female BALB/c mice were used as
donors for allogeneic and syngeneic settings, respectively. At
day 0, bone marrow cells (BMC) from donor femurs and
tibias were ﬂushed and single cell suspension was prepared.
Spleen(SP)singlecellsuspensionwaspreparedbydisrupting
the spleen. Cell number and viability was determined using
the Trypan blue exclusion assay. Recipient mice were injected
via the lateral tail vein with 2 ×107 and 3 ×107 cells of BMC
and SP in a volume of 250μl. All experiments described here
were approved by the South Stockholm ethics committee
for animal research. Transplantation experiments have been
repeated at three diﬀerent time points.
2.3. Assessment of GVHD. Recipient mice were examined
daily until the appropriate sampling day. Animals were
evaluated for ﬁve clinical symptoms of GVHD: weight loss,
posture, activity, fur texture, and skin integrity as described
elsewhere [5, 22]. Liver, intestine, and skin were evaluated
using histopathologic sections to conﬁrm GVHD.
2.4. Cell Surface Staining for Flow Cytometry. Fluoresce-
in isothiocyanate-(FITC) conjugated H-2Kb(clone: AF6-
88.5), H-2Kd(clone: SF1-1.1), CD3 (clone: AF6-88.5), NK
(clone: DX5), CD44 (clone: IM7), Ia-IE (clone: 2G9) and
Phycoerythrin-conjugated (PE) conjugated H-2Kd(clone:
SF1-1.1), CD8 (clone: 53-6.7), H-2Kb(clone: AF6-88.5) and
PerCP-Cy5.5 conjugated CD3 (clone: 145-2C11), CD25
(clone: PC61), CD11b (clone: M1/70) and APC conjugated
CD4 (clone: RM4-5), CD19 (clone: 1D3), CD62L (clone:
MEL-14), and CD11c (clone: HL3) were purchased from
Pharmingen (San Diego, California, USA). Spleen and bone
marrow single cell suspension were prepared as described
before [22].
For immunophenotyping, cells were ﬁrst incubated
with an FC-receptor blocking monoclonal antibody (clone:
2.4G2) for 15min at 4◦C and then directly stained with a
panel of mAbs for 30min at 4◦C. Finally, the stained cells
were washed twice with FACS buﬀer solution and analyzed
with a FACS Calibur ﬂowcytometer.
2.5. Cytokine Measurement. Blood (0.5–1ml) was collected
in an ependorf tube before killing the animals, serum was
separated and kept at −80◦C until analyzed using Gyrolab
Bioaﬀy (Gyros AB, Uppsala, Sweden).
AG y r o l a bB i o a ﬀy CD contains 112 individual
microstructures, each containing a 15nl prepacked column
with streptavidin-coated particles where the reaction takes
place. Liquids (capture reagent, sample and detection re-
agent) are sequentially introduced into each micro-structure
using capillary force, either through an individual inlet or a
commoninletthatconnectsandserveseightmicrostructures
via a common distribution channel. Each microstructure
contains a volume deﬁnition chamber and an overﬂow
channel enclosed by hydrophobic barriers. The volume
deﬁnition chamber allows accurate metering within the
CD of the sample portion intended for analysis (200nl).
Sample volume deﬁnition is incorporated as an integrated
part of the analytical process avoiding problems such as
evaporation and poor reproducibility commonly associated
with metering of nanoliter volumes. The ﬂow of liquid over
the column is further controlled by centrifugal force created
at appropriate spinning rates of the CD microlaboratory.Clinical and Developmental Immunology 3
Gyrolab Workstation Control Software automatically
controls the diﬀerent steps when running a Gyrolab Bioaﬀy
CD. Brieﬂy, the individual streptavidin-coated columns are
reconditioned by loading 0.01MPBS, pH 7.2 containing
0.01% Tween 20 (PBS-T) through each common channel.
The biotinylated capture antibody (500nl at 100μl/ml) is
then loaded through the common channel and 200nl is
spunoverthecapturebedforapproximately1mintosaturate
the streptavidin column. The column is then washed twice
adding PBS-T through the common channel followed by
rapid spinning. Protein calibrators to generate a reference
curve or unknown samples are then added through the
individual inlet holes into the microstructures (200nl)
followed by moderate spinning of the CD for approximately
3.5 minutes in order to slowly ﬂow the 200nl sample
through the column to maximize capture of the cytokine.
The column is rinsed twice by sequential addition of PBS-T
followed by rapid spinning. An excess of detection reagent, a
complementary antibody with a diﬀerent epitope speciﬁcity
and labeled with Alexa Fluor 647, is added through the
common channel. The CD is spun again at a moderate rate
to allow binding of the detection reagent to the captured
cytokine. Finally the columns are washed 5 times with PBS-T
and the CD is automatically transferred to the laser detection
position where detection is carried out automatically using
preselected detector settings for the laser-induced ﬂuores-
cence (LIF, NeHe 633nm) detector. Fluorescence data from
eachcolumnintheCDisfurtheranalyzedwithGyrolabEval-
uator software that is a Microsoft Excel add-in using XLFit
(IDBS, Guildford, UK) for curve ﬁtting. Gyrolab Evaluator
software generates standard curves and calculates the con-
centrations of unknown samples. In addition, an image of
the ﬂuorescence intensity in each individual column can be
displayed graphically by Gyrolab Viewer software to facilitate
evaluation of assay performance and for investigation of any
outliers.
The following capture antibodies were used: mab rat
antimouse IL-2 clone JES6-1A12 (R and D System), mab
rat anti-IFNγ clone R4-6A2 (BD Pharmingen), mab ham-
ster anti-TNFα clone TN3-19.12 (RandD System), and for
detection: mab rat antimouse IL-2 clone JES6-5H4 (RandD
System), mab rat anti-IFNγ clone AN-18 (BD Pharmingen),
and polyclonal goat anti-TNFα cat. nr AF-410-NA (R and
D System). Recombinant cytokines produced in E. coli were
used as standard proteins.
2.6. Histology and Immunohistochemistry. Tissue samples
were ﬁxed in neutral buﬀered formalin for 24hr, transferred
to 70% ethanol, dehydrated, and embedded in paraﬃn
according to standard procedures. Sections of 4μmw e r e
prepared and stained using Hematoxylin and Eosin for
histology evaluation.
For immunohistochemistry, tissues were embedded in
OCT (Histolab, Stockholm, Sweden) and frozen in N-
hexan cooled by dry ice. Immunohistochemical detection
of CD4 (RM4-5), and CD8 (53-6.7) were performed using
rat antimouse monoclonal antibodies (BD Pharmingen, San
Diego, CA, USA). Brieﬂy, 4-5μms e c t i o n sw e r ec u t ,ﬁ x e d
in cold (−20◦C) acetone for 3 minutes, dried (overnight),
rinsed with PBS, and treated with 3% H2O2 in methanol
and blocked by 4% goat serum in PBS. Primary antibodies
were diluted in the blocking solution and applied at 4◦Cf o r
one hour. After rinsing in PBS, a biotin-labelled secondary
goat antirat antibody was applied. Sections were incubated
with ABC-HRP complex (BD Pharmingen, San Diego, CA,
USA). Binding sites were visualized with diaminobenzi-
dine/hydrogenperoxide,andtheslidesﬁnallycounterstained
with hematoxylin.
2.7. Statistical Analysis. All data are expressed as mean ±
S.E. (standard error) unless otherwise stated. Diﬀerences
between allogeneic and syngeneic were analyzed using
Mann-Whitney (U-test).
P<. 05isconsideredstatisticallysigniﬁcant.Allstatistical
analyses were performed utilizing SPSS ver13.
3. Results
3.1. Myelo- and Lymphoablative Eﬀects of Chemotherapy
Conditioning on the Bone Marrow and Spleen. We inves-
tigated the eﬀect of conditioning regimen (Bu-Cy) on
the myeloid and lymphoid cells in the BM and spleen
at day 0 (day of BMT). As shown in Table 1,t r e a t e d
mice exhibited a substantial decrease in the total numbers
of bone marrow and spleen cellularity (95% and 63%,
resp.). Moreover, except na¨ ıve and cytotoxic T-lymphocytes,
all of the individual subpopulations in the bone marrow
and spleen were reduced signiﬁcantly in number by the
treatment (Table 1). In BM, cells within both lymphoid
(CD19+)andmyeloid(CD11b+)lineagesaswellasdendritic
(CD11c+) and natural killer (DX5, Pan-NK) cells were the
most aﬀected populations (Table 1) whereas in the spleen
mostly NK, dendritic and B cells were decreased (Table 1).
Nevertheless individual subpopulations were more sensitive
to conditioning in the BM compared to spleen. In both
organs, na¨ ıve T (CD44lowCD62high)and cytotoxic T (CD8+)
cellswerethemostresistantcellstotheconditioningregimen
(Table 1).
3.2. Recovery of the Bone Marrow and Spleen Cellularity at
Early Phase of GVHD. Recently, we have shown that clinical
and histopathological signs of GVHD started within 7 days
after allogeneic BMT [22]. In the present study, we evaluated
therecoverypatterninBMandrepopulationofimmunecells
in spleen during the development and progress of GVHD,
we followed the cellularity of bone marrow and spleen in
allogenic and syngeneic grafts at diﬀerent intervals (4–6 mice
ateachtimepoint).Insyngeneicrecipientmice(Figure1(a)),
therecoveryofBMcellularitywasinitiatedatday+1,reached
substantially high level on day +5 (>50% recovery), and
was fully recovered by day +21. However, in allogeneic
recipients, the bone marrow cellularity was delayed, had
lower magnitude (Figure 1(a)), and did not recover until day
+21 (Figure 1(a)).
Similar to the BM, repopulation in the spleen of syn-
geneic recipient mice was rapid (started at day +1), increased
by time (except for day +5, which showed a slight decrease),4 Clinical and Developmental Immunology
Table 1: Eﬀect of conditioning on the diﬀerent immune cell of bone marrow and spleen. Female BALB/c mice were treated with busulfan
(80mg/kg) followed by cyclophosphamide (200mg/kg). Bone marrow and spleen cellularity plus immune cell phenotype were evaluated
using ﬂowcytometry before and after conditioning. Total and individual immune cells in the bone marrow are more sensitive to the
conditioning compare to the spleen cells. 1CD3+CD4+, 2CD3+CD8+, 3CD44lowCD62high, 4CD44highCD62low, 5CD19+, 6DX5+, 7CD11c+,
and 8CD11b+. (∗P<. 05)
Time point Organ Cellularity T helper1 T
cytotoxic2
Na¨ ıve T
cells3
Eﬀector
memoryT
cells4
Bc e l l 5 NK cell6 DCs7 Myeloid
lineage8
Before
Conditioning
(D-7)
BM 39 ±0.50 .34 ±0.02 0.11 ±0.02 0.05 ±0.01 0.16 ±0.01 9 ±0.60 .6 ±0.06 0.44 ±0.04 15 ±0.32
After
Conditioning
(D0)
BM 2 ±0.20 .1 ±0.01 0.08 ±0.01 0.04 ±0.01 0.06 ±0.01 0.13 ±0.06 0.05 ±0.01 0.03 ±0.004 0.2 ±0.05
Decrement
(%) 95%∗ 71%∗ 27% 20% 63%∗ 99%∗ 92%∗ 93%∗ 99%∗
Before
Conditioning
(D-7)
SP 189 ±5.63 9 ±1.71 4 ±1.52 3 ±2.11 4 ±1.16 9 ±3.51 0 .4 ±15 ±0.3—
After
Conditioning
(D0)
SP 70 ±2.62 6 ±0.91 2 ±0.91 9 ±1.37 ±0.41 6 ±2.02 1.4 ±0.21 ±0.1—
Decrement
(%) 63%∗ 33%∗ 14% 17% 50%∗ 77%∗ 87%∗ 80%∗ —
∗P-value <. 01.
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Figure 1: Bone marrow and spleen cellularity in allogeneic and syngeneic transplanted mice. Female BALB/c mice were transplanted with
20 × 106 and 30 × 106 BM and SP cells, respectively, from male C57BL/6 or BALB/c mice as allogeneic or syngeneic setting. Bone marrow
(a) and spleen (b) cellularity at diﬀerent time points after conditioning and transplantation. (a) Bone marrow cellularity calculated based
on total cells extracted from both femurs. (b) Spleen cellularity determined based on 100mg of spleen tissue. ( ): allogeneic group, (♦):
syngeneic group and (O): control mice. All values are mean ± SE for 4 to 6 animals in each group per time point. Diﬀerences were analyzed
statistically employing U-test, compared between groups (∗P<. 05).Clinical and Developmental Immunology 5
andreachedto75%ofthecontrolafter21days(Figure1(b)).
In contrast, in allogeneic recipients, initial rapid increase of
splenic cellularity at day +1 was observed, followed by severe
decelerating until day +21. The numbers of splenocytes were
about25%ofthecontroland33%ofthesyngeneicrecipients
(Figure 1(b)).
3.3. Phenotype and Dynamics of the Recruited Immune
Cells at the Beginning of GVHD. Several studies [6, 7]
including ours [22] have shown that donor alloreactive cells
proliferate in the secondary lymphoid organs at day +5
and invade target tissues at day +7. Thus, we characterized
the phenotypes and activation status of the repopulated
immune cells in the spleen of recipient mice shortly after
BMT. As shown in Figure 2(a), in both allogeneic (GVHD)
and syngeneic recipient mice, the absolute numbers of cells
expressing DX5 (Pan-NK) slightly increased immediately
after BMT (day +1) and expanded until day +3 show-
ing more expansion in allogeneic compared to syngeneic
group. These cells began to decline continuously in the
allogeneic recipients and increased to reach the control
level at day 21 posttransplantation in the syngeneic setting
(Figure 2(a)).
Dendritic cells (DCs) have been shown to play an
important role in triggering of GVHD [17, 18]. As shown in
Figure 2(b), the absolute number of splenic DCs increased
in both allo- and syngeneic setting one day after BMT.
However, DCs were signiﬁcantly (P<. 01) higher (10-
fold) in allogeneic transplanted mice compared to that
seen in syngeneic and control groups (2-fold) (Figure 2(b))
at day +3. The higher number of DCs in the spleen of
GVHD mice was persistent up to day +5 compared to
that observed in the syngeneic group (P<. 05). Seven
days after BMT, the number of DCs in the spleen of allo-
geneic group started to decrease, while they recovered and
reached to normal level by day +21 in syngeneic recipients
(Figure 2(b)).
T-cell repopulation in the spleen of allogeneic and syn-
geneic transplanted mice showed that both groups exhibited
an immediate and slight expansion of CD4+ and CD8+ T-
cells up to three days after BMT (Figures 2(c) and 2(d)).
The magnitude of CD4+ T-cell reconstitution was higher in
syngeneic transplanted mice (P<. 05). Nonetheless, at day
+5, the population of CD4+ T-cells signiﬁcantly decreased
in the spleen of syngeneic group as compared to GVHD mice
(P<. 05).
In our previous investigation we have shown that
cytotoxic CD8+ cells are the principal cell type that initiates
GVHD and promotes tissue damage [22]. Interestingly, ﬁve
days after BMT while T-cell subpopulations were decreasing
in the spleen of syngeneic group, allogeneic transplanted
mice exhibited a vigorous expansion of CD8+ T-cells (230%
of control, P<. 01). Thereafter, at day +7, the sizes of both
populations (CD4+ and CD8+ T cells) declined and only
reached to 10% and 30% of controls at day +21 whereas
in syngeneic setting recovery of CD4+ and CD8+ T-cells
reached close to normal level at day +21 (Figures 2(c) and
2(d)).
3.4. Donor DCs Repopulate and Maturate at Early Phase of
GVHD. The ﬁnding that the pattern of DCs repopulation in
the spleen of allogeneic setting was strikingly diﬀerent from
that in the syngeneic transplanted mice (Figure 2(b)) raised
two questions: ﬁrstly, are these cells of donor or recipient
origin, and secondly, are these cells mature or activated?
To answer these questions, we ﬁrst analyzed the chimerism
status in GVHD prone allogeneic recipients. As shown in
Figure 3(a), while one day after the transplantation most of
DCs(>85%) in the spleen have the recipient origin (CD11c+
H-2Kd+), at the time at which DCs expand intensively
(day +3, Figure 2(b)), the majority (>65%) of these cells
are donor derived (CD11c+ H-2Kb+) (Figures 3(a) and
3(b)). Figure 3(b) represents the chronological pattern of
host versus donor DCs expansion in the spleen of GVHD
developing mice.
We further evaluated the activation (maturity) status
of the identiﬁed DCs in the spleen by measuring the
expression level of MHC-II (Ia-b) on these cells. As shown
in Figure 3(c), the expression level of Ia-IEb (MHC-II)
increased by time and reached the peak level (MFI = 2389) at
day +3 after transplantation and thereafter reduced by time
(Figure 3(c)).
3.5. Origin and Activation Status of Repopulated T Cells
During the Initiation Phase of GVHD. Dynamics of immune
cell repopulation in the spleen of allogeneic transplanted
mice showed that T-cells were increased by number (Figures
2(c) and 2(d)) at day +5 (two days after DCs maturation
and expansion). Therefore, we evaluated this population
to identify their origin and phenotype. As indicated in
Figure 4(a) the frequency of donor T-cells increase from
3.7±1.3%atday+3to58±15.5%atday+5afterBMT.While
donor T-cells were increasing during the transitional period
(day +3 to +5), recipient T-cells decreased from 96.3±1.3t o
42 ± 15.5 percent, respectively (Figure 4(a)).
We investigated the phenotype of T cells during GVHD
development in the spleen of recipient mice. As shown in
Figure 4(b), in allogeneic transplanted mice, a discernible
population of CD8 T-lymphocyte emerges 5 days after trans-
plantation. The new, granular, large lymphocytes appeared
at day +5 and signiﬁcantly decreased in number at day +7.
Of interest, >95% of the large granular lymphocytes (upper
gate) originate from the donor while small nongranulated
lymphocytes (lower gate) were of mixed of donor and host
origin (Figure 4(c)). Morphological analysis of the sorted
donor CD8+ T-cells (CD8+, H-2b+) from both upper and
lower gates showed that upper gate donor CD8+ cells have
a larger nucleus and more cytoplasm comparing to lower
gatecells(data not shown). Additionally ex vivo activation of
thesecellsindicatedthatlargegranularlymphocytesprolifer-
atemoreinresponsetoCon-Astimulation(datanotshown).
3.6. Donor Eﬀector Memory T Cells Develop from
Na¨ ıve T Cells during the Early Phase of GVHD. Both
na¨ ıve (CD44lowCD62high)a n de ﬀector memory (CD44high
CD62low) T-cells are capable to induce GVHD [23]. Thus,
it was of importance to elucidate how these T-cell subsets
emerge during the early stage of GVHD. To answer this6 Clinical and Developmental Immunology
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Figure 2: Immune cell phenotype and repopulation pattern in the spleen of allogeneic and syngeneic transplanted mice at the early phase
of GVHD. Female BALB/c mice were transplanted with 20×106 and 30×106 BM and SP cells, respectively, from male C57BL/6 (allogeneic)
or BALB/c (syngeneic) mice. Repopulations of diﬀerent immune cells were evaluated in the spleen of recipient mice. Absolute number of
(a) NK (DX5) (b) DCs (CD11c) (c) CD4 T helper and (d) CD8 cytotoxic T cells in 100mg of the spleen tissue in allogeneic and syngeneic
setting. ( ): allogeneic group, (♦): syngeneic group and (O): control mice. All values are mean ± SE for 4 to 6 animals in each group per
time point. Diﬀerences were analyzed statistically employing U-test, compared between groups (∗P<. 05).
question, the kinetics of donor chimerism as well as the
expression of CD44 and CD62 on the splenic T-cells was
determined. As shown in Figure 4(a), at the time of T-cell
expansion in the GVHD mice (day +5), about 58% of
T-cells in the spleen were of donor origin. Phenotype
analysis showed that the frequency of eﬀector-memory
(CD44highCD62low) T-cells increased from 17% (day +3)
to 52% at day +5, simultaneously the frequency of na¨ ıve
(CD44lowCD62high) T-cells reduced from 68% (day +3) to
31% at day +5 (Figure 4(d)). Moreover, by progression of
GVHD and T-cell inﬁltration to the tissue (day +21), the
frequency of the eﬀector-memory cells remained at same
level whereas na¨ ıve T-cell population stayed continuously at
the lower level (Figure 4(d)). In contrast, in syngeneic recip-
ient mice no increase in eﬀector-memory cell was detected
at day +5 or later and na¨ ıve T-cells (CD44lowCD62high)w e r e
higher than eﬀector-memory (CD44highCD62low) cells at all
evaluated time points (Figure 4(e)).Clinical and Developmental Immunology 7
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Figure 3: Dendritic cells chimerism and activation pattern in GVHD developing mice. Spleens of allogeneic transplanted recipients were
evaluated for dendritic cell chimerism and maturation marker. (a, b) Frequency and expansion pattern of donor (CD11c+ and H-2Kb)
versus host (CD11c+ and H-2Kd) dendritic cells in the spleen of recipient mice in GVHD developing setting. (c) Maturation status of DCs
was evaluated using expression level of MHC class II on DCs surface. Three days after BMT donor DCs has higher expansion with more
expression of maturation marker on cell surface. ( ): donor DCs (CD11c+ and H-2Kb), (♦): host DCs (CD11c+ and H-2Kd). All values
are mean ± SE for 4 to 6 animals in each group per time point. Diﬀerences were analyzed statistically employing U-test, compared between
groups (∗P<. 05).
3.7. Histopathologic Evaluation of T-Cells Expansion in the
Spleen of GVHD Developing Recipients at Early Time Point.
The expansion of CD4+ and CD8+ T-cells in the spleen of
allogeneic and syngeneic transplanted mice was examined
using immunohistochemistry. As shown in Figure 4(f),
CD8+ T-cells expansion is limited to white pulps both
in allogeneic and syngeneic transplanted mice three days
a f t e rB M T .H o w e v e r ,5d a y sa f t e rB M T ,t h eC D 8 +c e l l s
are spreading all over the spleen (not limited to white
pulp) in GVHD developing mice (Figure 4(f)). In sharp
contrast, at day +5 after BMT, the number of CD8+ T-
cells in the spleen of syngeneic mice dramatically decreases
and few existing cells were limited to white pulp (Fig-
ure 4(f)). Colonization pattern of CD8+ T-cells return to
normal situation in both allogeneic and syngeneic setting
7 days after BMT; however, the population was larger
in allogeneic comparing to syngeneic transplanted mice
(Figure 4(f)).8 Clinical and Developmental Immunology
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Figure 4: Chimerism and activation pattern of donor cytotoxic T cells in the spleen of GVHD mice. BALB/c mice were transplanted with
20 × 106 and 30 × 106 BM and SP cells from either allogeneic (C57BL/6) or syngeneic (BALB/c) donors. Spleens of transplanted recipients
were evaluated using ﬂowcytometry and histopathology methods. (a) Frequency of donor versus recipient T cells at diﬀerent time points in
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eﬀector memory (CD44highCD62low) in normal BALB/c mice. Diﬀerences were analyzed statistically employing U-test, compared between
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Altogether, these data conﬁrmed results obtained from
ﬂow cytometry (Figure 2(d)). The same pattern with less
intensity was observed in CD4+ T-cells (data not shown).
3.8. Kinetics of Inﬂammatory Cytokine Production during
the Early Stage of GVHD. It is well \pagebreak established
that proinﬂammatory cytokines play a central role in the
developmentofGVHD[20].ThekineticsofIL-2,IFN-γ,and
TNF-α production in the sera of GVHD mice demonstrated
(Figure 5(a)) that the serum level of IL-2 increased from
39 ± 13pg/ml at day −7 (control mice) to 93 ± 8.7pg/ml
(P<. 05) and 112 ± 20pg/ml (P<. 05) at days +3 and
+5, respectively, in parallel to DCs and T-cells expansion in
the spleen of allogeneic recipients. Syngeneic transplanted
mice did not show increment at these time points (data not
shown).
IFN-gamma and TNF-alpha are secreted during T-cell
proliferation and activation [24–26]. Figures 5(b) and 5(c)
represent serum level of IFN-gamma and TNF-alpha in
the allogeneic transplanted mice. Both cytokines reach peak
serum level at day +5 in GVHD developing mice which are
in line with donor T-cell proliferation and activation.
4. Discussion
Acute GVHD is a complex inﬂammatory process in which
several factors including conditioning, activation of donor
immune cells, and the production of proinﬂammatory
cytokines are suggested to play pivotal roles [1]. Condi-
tioning is an essential prerequisite for HSCT with multiple
functions including depletion of hematopoietic stem cells,
providing “space” for donor cells, suppression of the host
immune system, and most importantly eliminating tumor
cells in recipient with malignant disease [27–29]. In the
present study, we found that a combination of busulfan
and cyclophosphamide (Bu-Cy) as conditioning regimen
was able to deplete >95% of both myeloid and lymphoid
lineages in the bone marrow. This ﬁnding implies that this
regimen is myeloablative and thus provides “space” for the
donor cells. Bu-Cy regimen induced also a marked decrease
(>60%) in the number of splenocytes which suggest that
this regimen can also exert a potent immunosuppressive
eﬀect. Regarding this issue, we observed Bu-Cy caused a
modest(33%)reductioninthenumberofsplenicT-cellsand
induced a marked decrease in the numbers of B, DC, and NK
cells within the range 77%–87% in spleen. This observation
clearly implies that these latter immune cells are more sen-
sitive to chemotherapy-based conditioning compared to T-
cells. Interestingly murine T-cells were also found to be more
resistant to radiation compared to B-cells [30]. Although,
the underlying mechanisms for the diﬀerential sensitivity
of T- and B-cells to chemotherapy- and/or radiation-based
conditioning are not well understood, these ﬁndings suggest
that both regimens share similarities in depletion of immune
cells in the recipient.
Several studies have shown that the intensity of the con-
ditioning regimen is positively correlated with the incidence
and severity of GVHD which is accompanied by increased
damage of the gastrointestinal tract, increased translocation
of lipopolysaccaride (LPS) into the circulation and aug-
mented TNF-alfa production [10, 20, 31]. Our ﬁnding that
at the time of transplantation (day 0), circulatory levels of
proinﬂammatory cytokines, particularly TNF-alfa were low,
but markedly increased at the time of T-cell reconstitution
in the spleen suggests that in contrast to radiotherapy,
chemotherapy-based conditioning plays a minor role in
the development of GVHD. Obviously, further studies are
required to test this hypothesis.
In the pathogenesis of GVHD, the activation of allore-
active donor T-cells is the hallmark of the disease [2, 31].
The process of activation of alloreactive T-cells is similar
to the activation of nonalloreactive antigen speciﬁc T-cells
[32], that is, they are activated by the antigen presenting
cells (APCs), mainly DCs, which express alloantigens [21].
Studies have shown that the presentation of alloantigens to
donor T-cells can be performed either by the recipient’s [17]
or donor’s DCs [18, 33, 34]. Using an in vivo tracking model,
Beilhack et al. and Panoskaltsis-Mortari et al. have shown
the migration pattern of donor cells in the recipient’s body.
However, both reports did not show the chronobiology and
pattern of donor antihost immune cells at the early phase
of GVHD [6, 7]. Moreover, in the majority of experimental
models the immunobiology of GVHD, the main concern
focus on the established picture of disease [5, 17, 18]. To
explore the biological role of donor antihost immune cells
at the earliest time of GVHD, we studied the phenotypical
and expansion pattern of immune cells in the primary and
secondary lymphoid organs of GVHD developing mice.
In the present study, the chronological analysis of
immunecellreconstitutionshowedthatbothhostanddonor
DCs are expanded and activated in the early phase of GVHD.
In general, the expansion of host DCs was immediate (day
+1) and transient (decelerated by day +3), whereas the
expansion of donor DCs was intensive, developed later in the
course of GVHD (day +3) which preceded the activation of
donor T-cell (day +5) and remained in the expansion phase
until the development of clinical manifestations of GVHD.
These results suggest that donor DCs might have prominent
role (more than expected before) in activation of donor
alloreactive T-cells and play a pivotal role in the development
of GVHD. Nevertheless more functional studies need to be
done. It seems that transient host DCs expansion activate
part of donor alloreactive T-cells to recognize peptide-allo-
MHC complex, which might lead to the development of
a mild GVHD. In contrast, persistent presence of donor
DCs continuously activate allorecative T-cells (CD8+) that
recognize alloantigens via cross presentation process, which
intensiﬁes and perpetuates the development of GVHD. In
fact, this possibility is strongly supported by the observation
that although GVHD can develop in recipients receiv-
ing marrow with major MHC class I-deﬁciency (beta-2
microglubolin KO mice), but it is strongly potentiated in
recipients of bone marrow from wild type donor [18].
During the process of GVHD, activated donor T-cells
migrate to target tissue and induce damage via either direct
cell contact (cytotoxic T-cells) or cytokine mediated toxicity
(T-helper cells) [3, 31]. Despite intensive research about theClinical and Developmental Immunology 11
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Figure 5: Cytokine levels in the serum of GVHD developing mice. Inﬂammatory cytokine levels were measured in the serum of allogeneic
transplanted BALB/c mice at diﬀerent time points before and after BMT. (a) IL-2, (b) IFN gamma, and (c) TNF-alfa levels in the serum of
GVHD mice. All of the inﬂammatory cytokines showed maximum level 5 days after BMT in GVHD mice. Serum level of these cytokine
was not detectable in syngeneic setting. ( ): allogeneic setting Diﬀerences were analyzed statistically employing U-test, compared between
groups (∗P<. 05).
role of na¨ ıveand/oreﬀector-memoryT-cellsintheinduction
of tissue damage, only conﬂicting results are available. For
instance, several studies demonstrate that tissue damage
in acute GVHD is caused exclusively by activated na¨ ıve
alloreactive T-cells [35, 36], while others showed that
eﬀector-memory alloreactive T-cells are responsible for the
tissue destruction [23, 37, 38]. Our study, showed that at
the early phase of GVHD (day +3), most of the T-cells
have na¨ ıve phenotype (CD44lowCD62high) whereas at the
late phase (T-cells migration to the tissues, day +5 to day
+21), these cells are mainly of eﬀector-memory phenotype
(CD44highCD62low). These observations imply that upon
interaction with host/donor DCs, na¨ ıve alloreactive T-cells
are ﬁrstly activated and thereafter, converted to eﬀector-
memory alloreactive T-cells, which are able to migrate to the
target tissue and cause damage. This statement is supported
by ﬁnding that donor CD8+ T-cells recovered on day 42 after
allogeneic BMT were mainly of eﬀector-memory phenotype
and were able to induce virulent GVHD in secondary
recipients [23]. It is valuable to investigate further if the
blockade of eﬀector-memory alloreactive T cells can prevent
the development of GVHD in our murine model.
A peculiar observation in our study was that ﬁve days
after the allogeneic BMT, in addition to small and un-
granulated lymphocytes, a population of highly granulated
lymphocytes emerged in the recipient, which was mainly
originated from the donor and consisted of both CD4+ and
CD8+ cell populations. Interestingly, the emergence of this
population was synchronized with the peak of alloreactive
donor cell expansion and with the highest serum levels
of inﬂammatory cytokines. Thus, it is highly possible that
these granulated large lymphocytes are responsible for the12 Clinical and Developmental Immunology
induction of tissue damage and appearance of clinical mani-
festations. In fact, our ﬁndings that these cells disappeared in
the spleen by day +7, in addition to our previous observation
that at day +7, alloreactive T-cells migrate to the peripheral
tissues [22] support this hypothesis. Indeed, it is important
to separate and purify these granulated large lymphocytes
and investigate their role in GVHD and more importantly
if they can induce GVL. These studies are currently ongoing
in our laboratory.
In summary, our results show that GVHD early patho-
physiological events following bone marrow transplantation
based on busulfan/cyclophosphamide conditioning are sim-
ilar to that immune response observed in GVHD developed
after radiation-based HSCT. However, the rapid kinetics of
expansion, proliferation and activation of donor cells that
was observed in the present study might be due to the degree
of mismatch between donor and recipient. Moreover, the
phenotypical changes that occurred during early phase of
GVHD (in secondary lymphoid organ) were not detectable
among T-cells population after GVHD establishment. Our
present model of GVHD based on chemotherapy condi-
tioning regimen is reliable, reproducible, and may give the
opportunity to understand mechanisms underlying GVHD
in patients conditioned with Bu-Cy compared to that
following TBI.
Conﬂict of Interests
The authors have no conﬂict of interests to declare.
Acknowledgments
The authors express their gratitude for the Swedish Cancer
Foundation, the Swedish Children Cancer Society, Bank of
Muscat, Oman, and The Karolinska Institutet Funds for the
support provided to perform this investigation.
References
[1] M. Bleakley and S. R. Riddell, “Molecules and mechanisms of
the graft-versus-leukaemia eﬀect,” Nature Reviews Cancer, vol.
4, no. 5, pp. 371–380, 2004.
[2] C. A. Wysocki, A. Panoskaltsis-Mortari, B. R. Blazar, and J. S.
Serody, “Leukocyte migration and graft-versus-host disease,”
Blood, vol. 105, no. 11, pp. 4191–4199, 2005.
[ 3 ]Y .K a t a o k a ,T .I w a s a k i ,T .K u r o i w ae ta l . ,“ T h er o l eo fd o n o rT
cellsfortargetorganinjuriesinacuteandchronicgraft-versus-
host disease,” Immunology, vol. 103, no. 3, pp. 310–318, 2001.
[ 4 ] P .R e d d ya n dJ .L .M .F e r r a r a ,“ I m m u n o b i o l o g yo fa c u t eg r a f t -
versus-hostdisease,”BloodReviews,vol.17,no.4,pp.187–194,
2003.
[5] T. Teshima, R. Ordemann, P. Reddy et al., “Acute graft-versus-
host disease does not require alloantigen expression on host
epithelium,” Nature Medicine, vol. 8, no. 6, pp. 575–581,
2002.
[6] A. Beilhack, S. Schulz, J. Baker et al., “In vivo analyses of
earlyeventsinacutegraft-versus-hostdiseaserevealsequential
inﬁltration of T-cell subsets,” Blood, vol. 106, no. 3, pp. 1113–
1122, 2005.
[7] A. Panoskaltsis-Mortari, A. Price, J. R. Hermanson et al., “In
vivo imaging of graft-versus-host-disease in mice,” Blood, vol.
103, no. 9, pp. 3590–3598, 2004.
[8] T. Teshima and J. L. M. Ferrara, “Understanding the allore-
sponse: new approaches to graft-versus-host disease preven-
tion,” Seminars in Hematology, vol. 39, no. 1, pp. 15–22, 2002.
[9] H. Rappaport, A. Khalil, and O. Halle-Pannenko,
“Histopathologic sequence of events in adult mice undergoing
lethal graft-versus-host reaction developed across H-2 and/or
non-H-2 histocompatibility barriers,” American Journal of
Pathology, vol. 96, no. 1, pp. 121–142, 1979.
[ 1 0 ]G .R .H i l l ,J .M .C r a w f o r d ,K .R .C o o k e ,Y .S .B r i n s o n ,L .P a n ,
a n dJ .L .M .F e r r a r a ,“ T o t a lb o d yi r r a d i a t i o na n da c u t eg r a f t -
versus-host disease: the role of gastrointestinal damage and
inﬂammatory cytokines,” Blood, vol. 90, no. 8, pp. 3204–3213,
1997.
[11] J. A. Perez-Simon, M. Diez-Campelo, R. Martino et al.,
“Inﬂuence of the intensity of the conditioning regimen on
the characteristics of acute and chronic graft-versus-host
disease after allogeneic transplantation,” British Journal of
Haematology, vol. 130, no. 3, pp. 394–403, 2005.
[12] J.L.M.Ferrara,K.R.Cooke,andT.Teshima,“Thepathophys-
iologyofacutegraft-versus-hostdisease,”InternationalJournal
of Hematology, vol. 78, no. 3, pp. 181–187, 2003.
[13] M. Mielcarek, P. J. Martin, W. Leisenring et al., “Graft-
versus-host disease after nonmyeloablative versus conven-
tional hematopoietic stem cell transplantation,” Blood, vol.
102, no. 2, pp. 756–762, 2003.
[14] O. Ringden, T. Ruutu, M. Remberger et al., “A randomized
trial comparing busulfan with total body irradiation as
conditioning in allogeneic marrow transplant recipients with
leukemia: a report from the nordic bone marrow transplanta-
tion group,” Blood, vol. 83, no. 9, pp. 2723–2730, 1994.
[15] R. H. Collins Jr., O. Shpilberg, W. R. Drobyski et al., “Donor
leukocyte infusions in 140 patients with relapsed malignancy
after allogeneic bone marrow transplantation,” Journal of
Clinical Oncology, vol. 15, no. 2, pp. 433–444, 1997.
[16] F. T. Hakim, S. O. Sharrow, S. Payne, and G. M. Shearer,
“Repopulation of host lymphohematopoietic systems by
donor cells during graft-versus-host reaction in unirradiated
adult F1 mice injected with parental lymphocytes,” Journal of
Immunology, vol. 146, no. 7, pp. 2108–2115, 1991.
[17] W. D. Shlomchik, M. S. Couzens, C. B. Tang et al., “Prevention
of graft versus host disease by inactivation of host antigen-
presenting cells,” Science, vol. 285, no. 5426, pp. 412–415,
1999.
[18] C.C.Matte,J.Liu,J.Cormieretal.,“DonorAPCsarerequired
for maximal GVHD but not for GVL,” Nature Medicine, vol.
10, no. 9, pp. 987–992, 2004.
[19] Y. Zhang, G. Joe, E. Hexner, J. Zhu, and S. G. Emerson,
“Host-reactive CD8+ memory stem cells in graft-versus-host
disease,”Nature Medicine,vol.11,no.12,pp.1299–1305,2005.
[20] J. L. M. Ferrara and P. Reddy, “Pathophysiology of graft-
versus-host disease,” Seminars in Hematology, vol. 43, no. 1,
pp. 3–10, 2006.
[21] W. D. Shlomchik, “Graft-versus-host disease,” Nature Reviews
Immunology, vol. 7, no. 5, pp. 340–352, 2007.
[22] B. Sadeghi, N. Aghdami, Z. Hassan et al., “GVHD after
chemotherapy conditioning in allogeneic transplanted mice,”
Bone Marrow Transplantation, vol. 42, no. 12, pp. 807–818,
2008.Clinical and Developmental Immunology 13
[ 2 3 ] S .D u t t ,D .T s e n g ,J .E r m a n ne ta l . ,“ N a i v ea n dm e m o ryTc e l l s
induce diﬀerent types of graft-versus-host disease,” Journal of
Immunology, vol. 179, no. 10, pp. 6547–6554, 2007.
[ 2 4 ]T .K a s a h a r a ,J .J .H o o k s ,S .F .D o u g h e r t y ,a n dJ .J .O p p e n -
heim, “Interleukin 2-mediated immune interferon (IFN-γ)
production by human T cells and T cell subsets,” Journal of
Immunology, vol. 130, no. 4, pp. 1784–1789, 1983.
[25] S. Yokota, T. D. Geppert, and P. E. Lipsky, “Enhancement of
antigen- and mitogen-induced human T lymphocyte prolifer-
ation by tumor necrosis factor-α,” Journal of Immunology, vol.
140, no. 2, pp. 531–536, 1988.
[26] E. C. Ebert, “Tumour necrosis factor-α enhances intraepithe-
lial lymphocyte proliferation and migration,” Gut, vol. 42, no.
5, pp. 650–655, 1998.
[27] G. W. Santos, “Preparative regimens: chemotherapy versus
chemoradiotherapy. A historical perspective,” Annals of the
New York Academy of Sciences, vol. 770, pp. 1–7, 1995.
[28] V. J. Wiebe, B. R. Smith, M. W. DeGregorio, and J. M.
Rappeport, “Pharmacology of agents used in bone marrow
transplant conditioning regimens,” Critical Reviews in Oncol-
ogy/Hematology, vol. 13, no. 3, pp. 241–270, 1992.
[29] H. M. Vriesendorp, “Aims of conditioning,” Experimental
Hematology, vol. 31, no. 10, pp. 844–854, 2003.
[30] R. E. Anderson and N. L. Warner, “Ionizing radiation and the
immune response,” Advances in Immunology, vol. 24, pp. 215–
335, 1976.
[31] V. T. Ho and R. J. Soiﬀer, “The history and future of T-
cell depletion as graft-versus-host disease prophylaxis for
allogeneic hematopoietic stem cell transplantation,” Blood,
vol. 98, no. 12, pp. 3192–3204, 2001.
[32] J. Banchereau, F. Briere, C. Caux et al., “Immunobiology of
dendritic cells,” Annual Review of Immunology, vol. 18, pp.
767–811, 2000.
[33] U. A. Duﬀner, Y. Maeda, K. R. Cooke et al., “Host dendritic
cells alone are suﬃcient to initiate acute graft-versus-host
disease,” Journal of Immunology, vol. 172, no. 12, pp. 7393–
7398, 2004.
[ 3 4 ]B .E .A n d e r s o n ,J .M .M c N i ﬀ, D. Jain, B. R. Blazar, W.
D. Shlomchik, and M. J. Shlomchik, “Distinct roles for
donor- and host-derived antigen-presenting cells and costim-
ulatorymoleculesinmurinechronicgraft-versus-hostdisease:
requirements depend on target organ,” Blood, vol. 105, no. 5,
pp. 2227–2234, 2005.
[35] B. E. Anderson, J. McNiﬀ, J. Yan et al., “Memory CD4+ T cells
do not induce graft-versus-host disease,” Journal of Clinical
Investigation, vol. 112, no. 1, pp. 101–108, 2003.
[36] Y. Zhang, G. Joe, J. Zhu et al., “Dendritic cell-activated
CD44CD8+ T cells are defective in mediating acute graft-
versus-host disease but retain graft-versus-leukemia activity,”
Blood, vol. 103, no. 10, pp. 3970–3978, 2004.
[37] Y.Zhang,G.Joe,E.Hexner,J.Zhu,andS.G.Emerson,“Allore-
active memory T cells are responsible for the persistence of
graft-versus-hostdisease,”JournalofImmunology,vol.174,no.
5, pp. 3051–3058, 2005.
[38] H. Moncrieﬀe, M. Coles, and B. Stockinger, “The inﬂuence of
CD4 T-cell subsets on control of CD4 T-cell-mediated graft-
versus-hostdisease,”Immunology,vol.125,no.4,pp.459–468,
2008.